GLP1R and Insulin resistance: For the cluster #4 insulin resistance, the main research topic was the cardiovascular protective effects of anti-diabetic medications due to improved postprandial lipids metabolism, particularly, incretin-based drugs including dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists (62, 63).